How has the bile duct cancer market evolved, and where is it heading next?
The bile duct cancer market size has grown strongly in recent years. It will grow from $2.39 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increased exposure to toxic chemicals, increased awareness of bile duct cancer, a rising geriatric population, increasing incidence of bile duct and pancreatic cancers, and increased investment in healthcare infrastructure.
The bile duct cancer market size is expected to see strong growth in the next few years. It will grow to $3.63 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to the increasing incidence of bile duct cancer, rising incidents of cases of bile duct cancer and liver cancer, an increase in the incidence of biliary tract cancers (BTCs), an increase in the number of research and development activities, and rising demand for advanced treatment. Major trends in the forecast period include advancements in diagnostic techniques, advancements in medical technology, advancements in endoscopic imaging techniques, technological innovations, and expansion of personalized medicine approaches.
Get Your Free Sample of The Global Bile Duct Cancer Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21113&type=smp
What are the key drivers behind the rapid expansion of the bile duct cancer market?
The rising prevalence of liver diseases is expected to propel the growth of bile duct cancer going forward. Liver diseases refer to a range of conditions that affect the liver’s ability to function properly, including hepatitis, cirrhosis, fatty liver disease, and liver cancer. The rising prevalence of liver diseases is primarily driven by factors such as increased alcohol consumption, unhealthy diets, obesity, viral infections like hepatitis, and a lack of regular physical activity. Bile duct cancer can help in understanding liver diseases by highlighting the critical role of bile ducts in liver function, as their obstruction or dysfunction often leads to liver-related complications such as jaundice and cholestasis. For instance, in Apr 2024, according to The House of Commons Library, a UK-based government department, in 2022, 10,593 individuals under the age of 75 in England died from liver disease, marking a continued upward trend in mortality rates. The rate increased from 21.2 per 100,000 population in 2021 to 21.4 per 100,000 in 2022. Therefore, rising prevalence of liver diseases is driving the growth of the bile duct cancer market.
What is the segmentation for the bile duct cancer market?
The bile duct cancer market covered in this report is segmented –
1) By Type: Extrahepatic Bile Duct Cancer (eCCA), Intrahepatic Bile Duct Cancer (iCCA)
2) By Treatment Type: Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy
3) By Stage of Disease: Localized, Regional, Distant
4) By Diagnosis Type: Imaging Tests, Biopsy, Blood Tests
5) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Cancer Research Institutes
Subsegments:
1) By Extrahepatic Bile Duct Cancer (eCCA): Perihilar Cholangiocarcinoma (Klatskin Tumor), Distal Cholangiocarcinoma
2) By Intrahepatic Bile Duct Cancer (iCCA): Mass-Forming iCCA, Periductal Infiltrating iCCA, Intraductal Growth iCCA
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/bile-duct-cancer-global-market-report
Who are the most influential companies in the bile duct cancer market?
Major companies operating in the bile duct cancer market are AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Merck & Co. Inc., Boehringer Ingelheim International GmbH, Eisai Co. Ltd., Genentech Inc., Jazz Pharmaceuticals plc, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Mirati Therapeutics Inc., RenovoRx Inc., Spectrum Pharmaceuticals Inc., Specialised Therapeutics Pty Ltd, Taiho Pharmaceutical Co. Ltd.
What are the most influential trends expected to drive the bile duct cancer market forward?
Major companies operating in the bile duct cancer market are focused on developing innovative solutions, such as targeted therapies, to improve treatment outcomes, reduce side effects, and offer new hope for patients with this rare and challenging cancer. Targeted therapies are treatments designed to focus on specific genes, proteins, or molecules that help cancer cells grow. These therapies work by blocking the processes that allow cancer to grow, aiming to stop tumor growth, reduce side effects, and improve treatment results. For instance, in August 2023, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, announced the launch of FGFR Inhibitor LYTGOBI Tablets 4m. The tablet formulation of LYTGOBI offers a convenient oral administration option, enhancing patient compliance and ease of treatment. This launch provides a new therapeutic option for patients with advanced or metastatic bile duct cancer, particularly those who harbor FGFR2 fusion or rearrangement mutations, thereby addressing a critical unmet need in cancer care.
What are the major regional insights for the bile duct cancer market, and which region holds the top position?
North America was the largest region in the bile duct cancer market in 2024. The regions covered in the bile duct cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Bile Duct Cancer Market Report 2025 Offer?
The bile duct cancer market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Bile duct cancer refers to a rare type of cancer that forms in the bile ducts, which are the tubes that carry bile from the liver to the gallbladder and small intestine. It is typically diagnosed in its advanced stages and can lead to symptoms such as jaundice, weight loss, and abdominal pain.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21113
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
